Rx/reimbursement adult incontinence saw no notable impact from COVID-19, with volume and value growth rates remaining similar, albeit slightly higher than that seen in 2020. There was a small deceleration in the first year of the pandemic as consumers were more reluctant to go to the doctor, as they viewed surgeries or hospitals as a prime place to contract the virus.
In France, non-prescribed adult incontinence products are generally not reimbursed by the public healthcare insurance scheme, which means sales are low compared with retail adult incontinence. For example, French Social Security does not reimburse absorbent protections, except in the event of dependency or disability.
As COVID-19 has not had an impact on sales of Rx/reimbursement adult incontinence, the volume and current value growth rates in this category are expected to continue at similar levels in 2022 and for the rest of the forecast period. The rise in the over 65 population, number of residents in nursing homes, and greater consumer awareness will be the main drivers of growth over forecast period.
With the French government looking to substantially reduce its social security deficit, especially considering the heavy impact of the pandemic, the scope for reimbursement is set to remain closely restricted over the forecast period. Under the existing Rx/reimbursement system, payment is made through the public healthcare insurance scheme according to a predetermined reimbursement list.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Understand the latest market trends and future growth opportunities for the Rx/Reimbursement adult incontinence industry in France with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Rx/Reimbursement adult incontinence industry in France, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
To qualify for reimbursement, typically a note from a physician is required (a “prescription”) indicating that the patient is in need of incontinence supplies. Depending on the local system in place, supplies are then either shipped directly to consumer home by a designated service or a consumer has to pick up products at a pharmacy. Please be advised that services and routes to consumers can vary even within the same country and vary by state/region. Some countries provide reimbursement through income tax deductions. If this is the case in your market, we EXCLUDE this type of reimbursement from our Rx/Reimbursement coverage as it would be impossible to track. Additionally, consumers would have already purchased the products in retail before claiming tax deductions, and as such the products have already been counted as retail sales. The same logic applies to institutional sales. If a nursing home purchased adult incontinence products from a distributor/manufacturer for distribution to its patients/residents, these products would be included as AFH adult incontinence in our coverage, even though sometimes patients might claim healthcare deductions for costs of stay at a nursing home.See All of Our Definitions
This report originates from Passport, our Rx/Reimbursement adult incontinence research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!